Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) General Information

Description

Portfolio of stomach disease drugs based in the United States. The drug is used to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Roche
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)‘s full profile, request access.

Request a free trial

Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)‘s full profile, request access.

Request a free trial

Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) FAQs

  • Where is Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) headquartered?

    Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) is headquartered in .

  • What industry is Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) in?

    Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)’s primary industry is Buildings and Property.

  • Is Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) a private or public company?

    Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) is a Private company.

  • What is the current valuation of Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)?

    The current valuation of Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) is .

  • What is Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)’s current revenue?

    The current revenue for Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) is .

  • Who are Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)’s investors?

    Roivant Sciences has invested in Roivant Sciences (Stomach Disease Treatment Drug RVT-3101).

  • When was Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) acquired?

    Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) was acquired on 14-Dec-2023.

  • Who acquired Roivant Sciences (Stomach Disease Treatment Drug RVT-3101)?

    Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) was acquired by Roche.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process